Provided by Tiger Trade Technology Pte. Ltd.

Protagonist Therapeutics

154.72
+0.40000.26%
Post-market: 153.72-1.0000-0.65%19:30 EDT
Volume:483.34K
Turnover:74.35M
Market Cap:10.01B
PE:150.21
High:158.08
Open:154.32
Low:149.94
Close:154.32
52wk High:160.81
52wk Low:54.50
Shares:64.71M
Float Shares:63.17M
Volume Ratio:0.90
T/O Rate:0.77%
Dividend:- -
Dividend Rate:- -
EPS(TTM):1.03
EPS(LYR):-2.0500
ROE:10.98%
ROA:4.55%
PB:11.90
PE(LYR):-75.47

Loading ...

Protagonist Therapeutics price target raised to $116 from $104 at Clear Street

TIPRANKS
·
Apr 07

Assessing Protagonist Therapeutics (PTGX) Valuation After Strong 1‑Year Shareholder Return

Simply Wall St.
·
Mar 29

Protagonist says ICOTYDE Phase 3 one-year psoriasis data show durable skin clearance

Reuters
·
Mar 28

Protagonist Therapeutics Executives Quietly Cash In on Major Insider Stock Sales

TIPRANKS
·
Mar 28

J&J Exits 3 Biotechs, Retains Stakes in 2 Possible Acquisitions -- Barron's

Dow Jones
·
Mar 28

Protagonist Therapeutics; Chief Medical Officer Arturo Molina disposes of 15,000 common shares valued at $1,572,000

Reuters
·
Mar 28

Protagonist Therapeutics director Harold E. Selick disposes of 24,000 common shares; value drops to $2,520,000

Reuters
·
Mar 28

Protagonist Therapeutics CFO Ali Asif disposes of common shares; sale totals $2,581,000

Reuters
·
Mar 28

Protagonist Therapeutics President and CEO Dinesh V. Patel disposes of 54,700 common shares; value drops to $5,524,000

Reuters
·
Mar 26

Analysts Are Bullish on Top Healthcare Stocks: Protagonist Therapeutics (PTGX), MDxHealth (MDXH)

TIPRANKS
·
Mar 23

Protagonist's Oral Peptide Platform Validated With Icotyde Approval for Psoriasis, Wedbush Says

MT Newswires Live
·
Mar 20

Protagonist price target raised to $110 from $107 at Leerink

TIPRANKS
·
Mar 19

Protagonist Therapeutics Is Maintained at Overweight by Barclays

Dow Jones
·
Mar 19

Johnson & Johnson-Protagonist Therapeutics Partnered New Psoriasis Pill Wins FDA Nod, Shakes Up Competition With AbbVie

Benzinga_recent_news
·
Mar 19

Wedbush Raises Price Target on Protagonist Therapeutics to $112 From $100, Keeps Outperform Rating

MT Newswires Live
·
Mar 19

Protagonist Therapeutics Inc : Wedbush Raises Target Price to $112 From $100

THOMSON REUTERS
·
Mar 19

Analysts Offer Insights on Healthcare Companies: Stoke Therapeutics (STOK), Valneva (VALN) and Protagonist Therapeutics (PTGX)

TIPRANKS
·
Mar 19

Protagonist Therapeutics price target raised to $119 from $113 at Barclays

TIPRANKS
·
Mar 19

Protagonist Therapeutics (PTGX) Receives a Buy from Barclays

TIPRANKS
·
Mar 19

Protagonist Therapeutics price target raised to $104 from $91 at Clear Street

TIPRANKS
·
Mar 19